These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Assessment of online adaptive MR-guided stereotactic body radiotherapy of liver cancers. Padgett KR; Simpson G; Asher D; Portelance L; Bossart E; Dogan N Phys Med; 2020 Sep; 77():54-63. PubMed ID: 32781388 [TBL] [Abstract][Full Text] [Related]
8. MR-guided adaptive versus ITV-based stereotactic body radiotherapy for hepatic metastases (MAESTRO): a randomized controlled phase II trial. Hoegen P; Zhang KS; Tonndorf-Martini E; Weykamp F; Regnery S; Naumann P; Lang K; Ristau J; Körber SA; Dreher C; Buchele C; Rippke C; Renkamp CK; Paul KM; König L; Büsch C; Krisam J; Sedlaczek O; Schlemmer HP; Niyazi M; Corradini S; Debus J; Klüter S; Hörner-Rieber J Radiat Oncol; 2022 Mar; 17(1):59. PubMed ID: 35346270 [TBL] [Abstract][Full Text] [Related]
9. In Silico Single-Fraction Stereotactic Ablative Radiation Therapy for the Treatment of Thoracic and Abdominal Oligometastatic Disease With Online Adaptive Magnetic Resonance Guidance. Lee S; Yadav P; van der Kogel AJ; Bayouth J; Bassetti MF Adv Radiat Oncol; 2021; 6(3):100652. PubMed ID: 34195490 [TBL] [Abstract][Full Text] [Related]
10. Clinical outcomes of MR-guided adrenal stereotactic ablative radiotherapy with preferential sparing of organs at risk. Schneiders FL; van Vliet C; Giraud N; Bruynzeel AME; Slotman BJ; Palacios MA; Senan S Clin Transl Radiat Oncol; 2023 Nov; 43():100680. PubMed ID: 37808454 [TBL] [Abstract][Full Text] [Related]
11. Outcomes and toxicities in oligometastatic patients treated with stereotactic body radiotherapy for adrenal gland metastases: A multi-institutional retrospective study. Baydoun A; Chen H; Poon I; Badellino S; Dagan R; Erler D; Foote MC; Louie AV; Redmond KJ; Ricardi U; Sahgal A; Biswas T Clin Transl Radiat Oncol; 2022 Mar; 33():159-164. PubMed ID: 35243027 [TBL] [Abstract][Full Text] [Related]
12. Dosimetric Benefit of Adaptive Magnetic Resonance-Guided Stereotactic Body Radiotherapy of Liver Metastases. Weykamp F; Katsigiannopulos E; Piskorski L; Regnery S; Hoegen P; Ristau J; Renkamp CK; Liermann J; Forster T; Lang K; König L; Rippke C; Buchele C; Debus J; Klüter S; Hörner-Rieber J Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551527 [TBL] [Abstract][Full Text] [Related]
13. Stereotactic body radiotherapy (SBRT) for adrenal metastases of oligometastatic or oligoprogressive tumor patients. König L; Häfner MF; Katayama S; Koerber SA; Tonndorf-Martini E; Bernhardt D; von Nettelbladt B; Weykamp F; Hoegen P; Klüter S; Susko MS; Debus J; Hörner-Rieber J Radiat Oncol; 2020 Feb; 15(1):30. PubMed ID: 32019553 [TBL] [Abstract][Full Text] [Related]
14. Benefit of replanning in MR-guided online adaptive radiation therapy in the treatment of liver metastasis. Mayinger M; Ludwig R; Christ SM; Dal Bello R; Ryu A; Weitkamp N; Pavic M; Garcia Schüler H; Wilke L; Guckenberger M; Unkelbach J; Tanadini-Lang S; Andratschke N Radiat Oncol; 2021 May; 16(1):84. PubMed ID: 33947429 [TBL] [Abstract][Full Text] [Related]
15. Dosimetric benefit of online treatment plan adaptation in stereotactic ultrahypofractionated MR-guided radiotherapy for localized prostate cancer. Fink CA; Buchele C; Baumann L; Liermann J; Hoegen P; Ristau J; Regnery S; Sandrini E; König L; Rippke C; Bonekamp D; Schlemmer HP; Debus J; Koerber SA; Klüter S; Hörner-Rieber J Front Oncol; 2024; 14():1308406. PubMed ID: 38425342 [TBL] [Abstract][Full Text] [Related]
16. Phase I trial of stereotactic MR-guided online adaptive radiation therapy (SMART) for the treatment of oligometastatic or unresectable primary malignancies of the abdomen. Henke L; Kashani R; Robinson C; Curcuru A; DeWees T; Bradley J; Green O; Michalski J; Mutic S; Parikh P; Olsen J Radiother Oncol; 2018 Mar; 126(3):519-526. PubMed ID: 29277446 [TBL] [Abstract][Full Text] [Related]
17. Clinical Outcomes of Online Adaptive Magnetic Resonance-Guided Stereotactic Body Radiotherapy of Adrenal Metastases from a Single Institution. Hoegen-Saßmannshausen P; Jessen I; Buchele C; Schlüter F; Rippke C; Renkamp CK; Weykamp F; Regnery S; Liermann J; Meixner E; Hoeltgen L; Eichkorn T; König L; Debus J; Klüter S; Hörner-Rieber J Cancers (Basel); 2024 Jun; 16(12):. PubMed ID: 38927978 [TBL] [Abstract][Full Text] [Related]
18. Dosimetric Benefits and Practical Pitfalls of Daily Online Adaptive MRI-Guided Stereotactic Radiation Therapy for Pancreatic Cancer. El-Bared N; Portelance L; Spieler BO; Kwon D; Padgett KR; Brown KM; Mellon EA Pract Radiat Oncol; 2019 Jan; 9(1):e46-e54. PubMed ID: 30149192 [TBL] [Abstract][Full Text] [Related]
19. Factors influencing local control after MR-guided stereotactic body radiotherapy (MRgSBRT) for adrenal metastases. Ugurluer G; Schneiders FL; Corradini S; Boldrini L; Kotecha R; Kelly P; Portelance L; Camilleri P; Ben-David MA; Poiset S; Marschner SN; Panza G; Kutuk T; Palacios MA; Castelluccia A; Zoto Mustafayev T; Atalar B; Senan S; Ozyar E Clin Transl Radiat Oncol; 2024 May; 46():100756. PubMed ID: 38450219 [TBL] [Abstract][Full Text] [Related]
20. The role of online MR-guided multi-fraction stereotactic ablative radiotherapy in lung tumours. Hering S; Nieto A; Marschner S; Hofmaier J; Schmidt-Hegemann NS; da Silva Mendes V; Landry G; Niyazi M; Manapov F; Belka C; Corradini S; Eze C Clin Transl Radiat Oncol; 2024 Mar; 45():100736. PubMed ID: 38433949 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]